Home/Filings/4/0001140361-24-041410
4//SEC Filing

Davis Andrew S. 4

Accession 0001140361-24-041410

CIK 0001397702other

Filed

Sep 17, 8:00 PM ET

Accepted

Sep 18, 8:27 PM ET

Size

19.1 KB

Accession

0001140361-24-041410

Insider Transaction Report

Form 4
Period: 2024-09-17
Davis Andrew S.
EVP Global Sales & Marketing
Transactions
  • Award

    Common Stock

    2024-09-17+42,21842,218 total
  • Disposition to Issuer

    Common Stock

    2024-09-17290,0770 total
  • Disposition to Issuer

    Common Stock

    2024-09-1742,2180 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-09-17$22.77/sh62,958$1,433,5540 total
    Exercise: $4.73Exp: 2027-11-30Common Stock (62,958 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-09-17$7.50/sh33,220$249,1500 total
    Exercise: $20.00Exp: 2029-04-03Common Stock (33,220 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-09-17$25.90/sh22,033$570,6550 total
    Exercise: $1.60Exp: 2025-12-03Common Stock (22,033 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-09-17$21.39/sh1,853$39,6360 total
    Exercise: $6.11Exp: 2028-09-13Common Stock (1,853 underlying)
Footnotes (10)
  • [F1]Of the reported shares, 219,965 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
  • [F10]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $249,150.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
  • [F2]Includes 370 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on September 13, 2024.
  • [F3]Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
  • [F4]Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
  • [F5]Immediately prior to the effective time of the merger, certain RSUs subject to the achievement of performance-based criteria, or PSUs, were deemed achieved and certified by the Issuer's compensation committee.
  • [F6]Pursuant to the Merger Agreement, each PSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the PSUs, less applicable taxes and authorized deductions.
  • [F7]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $570,654.70, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
  • [F8]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,433,553.66, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
  • [F9]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $39,635.67, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Issuer

Silk Road Medical Inc

CIK 0001397702

Entity typeother

Related Parties

1
  • filerCIK 0001770191

Filing Metadata

Form type
4
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 8:27 PM ET
Size
19.1 KB